How does iron supplementation interfere with levothyroxine absorption?

Iron Interferes with Levothyroxine Through Direct Chelation in the Gastrointestinal Tract

Iron supplements form insoluble chelate complexes with levothyroxine in the stomach and intestine, physically binding the medication and preventing its absorption into the bloodstream. This interaction can result in persistently elevated TSH levels and inadequate thyroid hormone replacement despite appropriate levothyroxine dosing 1.

Mechanism of Interference

Iron salts (particularly ferrous sulfate, ferrous fumarate, and ferrous gluconate) directly bind to levothyroxine molecules through chelation when both are present in the gastrointestinal tract simultaneously. This chemical binding creates an insoluble complex that cannot be absorbed through the intestinal wall, effectively reducing the bioavailability of levothyroxine 2.

The clinical impact is substantial: population-based data demonstrates that iron supplementation increases serum TSH by an average of 0.22 mU/L (P < 0.001), with 7.5% of patients experiencing a clinically significant TSH increase of over 5 mU/L 2. This represents a meaningful reduction in levothyroxine effectiveness that can lead to undertreated hypothyroidism.

Critical Timing Considerations

Standard Separation Recommendations

The FDA-approved levothyroxine labeling explicitly states: "Instruct patients not to take levothyroxine sodium tablets within 4 hours of these agents" referring to iron and calcium supplements 1. This 4-hour separation window is the minimum recommended interval to minimize interaction 1.

The 2012 AACE/ATA guidelines reinforce that levothyroxine "should not be taken with substances or medications that interfere with its absorption or metabolism" 3.

Important Caveat: Separation May Not Always Be Sufficient

A critical 2026 case report reveals that the standard 4-hour separation may be inadequate in some patients 4. A 44-year-old woman maintained severe biochemical hypothyroidism (TSH >100 mU/L) despite taking levothyroxine 250 µg in the morning and iron at night—ensuring greater than 4-hour separation. Only after discontinuing oral iron and switching to intravenous iron did her TSH normalize to 0.42 mU/L within six weeks 4. This suggests that in certain individuals, even appropriate dose separation cannot fully prevent the interaction.

Practical Management Algorithm

For Patients Requiring Both Medications:

1. First-line approach: Separate levothyroxine and iron by at least 4 hours

   • Take levothyroxine on empty stomach, 30-60 minutes before breakfast 3
   • Take iron at a different time of day (e.g., evening or midday)

2. Monitor TSH closely: Check TSH 4-8 weeks after initiating iron supplementation 3

3. If TSH remains elevated despite separation:

   • Verify patient adherence to timing instructions
   • Consider switching to liquid levothyroxine formulation 5
   • Consider switching to intravenous iron if oral iron is causing persistent interference 4

Alternative Formulations That Circumvent the Interaction

Liquid levothyroxine formulations can be taken simultaneously with iron supplements without impaired absorption 6, 7, 5. A 2017 study demonstrated that switching from tablet to liquid levothyroxine at the same dose resulted in TSH normalization in 95% of patients who had malabsorption due to iron or calcium, with mean TSH decreasing from 7.48 to 1.95 mU/L (P < 0.001) 5. The effect was evident at the first follow-up visit (6-8 weeks), avoiding the need for frequent dose adjustments 5.

Soft-gel capsule formulations also show promise in circumventing drug interactions, though more studies are needed to confirm this specifically for iron 7, 8.

Clinical Pitfalls to Avoid

• Don't assume compliance is the only issue: When patients on high-dose levothyroxine (>200 µg/d) have persistently elevated TSH, drug interactions like iron are frequently under-recognized causes 3, 4

• Don't overlook concurrent iron supplementation: Iron deficiency and hypothyroidism commonly coexist, particularly in women of reproductive age 6

• Don't rely solely on dose separation in refractory cases: If TSH fails to normalize despite appropriate timing, consider liquid formulations or IV iron rather than continuing to escalate levothyroxine doses 4, 5

• Don't forget to recheck TSH after stopping iron: If iron supplementation is discontinued, levothyroxine requirements may decrease, potentially leading to overtreatment 2

The interaction between iron and levothyroxine represents a clinically significant pharmacokinetic interference that requires proactive management through appropriate dose timing, formulation selection, and vigilant TSH monitoring 1, 2.